CBD Oil: Evidence-Based Benefits for Pain, Anxiety, and Neuroinflammation

From Stigma to Pharmacology

Cannabidiol (CBD) is one of over 100 phytocannabinoids in Cannabis sativa. Unlike tetrahydrocannabinol (THC), CBD has no psychoactive properties and does not cause intoxication. The WHO concluded in its 2018 report that CBD "exhibits no effects indicative of any abuse or dependence potential."

Epidiolex — pure CBD — became the first cannabinoid-derived medication approved by the FDA (2018) for treating rare forms of epilepsy (Lennox-Gastaut and Dravet syndromes). This approval legitimized CBD as a pharmacologically active substance with proven clinical efficacy.

The Endocannabinoid System (ECS)

The endocannabinoid system is a fundamental regulatory system discovered in the 1990s. It comprises three components: endocannabinoids (anandamide and 2-AG), cannabinoid receptors (CB1 and CB2), and synthesis/degradation enzymes (FAAH, MAGL).

CB1 receptors are predominantly in the central nervous system (especially hippocampus, basal ganglia, cerebellum, neocortex). They regulate neurotransmission, pain, mood, appetite, and memory.

CB2 receptors are predominantly in immune cells (microglia, macrophages, spleen). They regulate inflammation, immune response, and neuroinflammation.

CBD does not directly bind CB1/CB2 receptors (unlike THC). Instead, it acts as a negative allosteric modulator of CB1 and indirectly raises endocannabinoid levels by inhibiting FAAH (the enzyme that degrades anandamide). Additionally, CBD interacts with serotonin 5-HT1A receptors, TRPV1 receptors (pain modulation), and PPARgamma receptors (anti-inflammatory).

CBD for Chronic Pain

### Pain Mechanisms

CBD modulates the pain signal at multiple levels: 1) TRPV1 receptor activation (pain neuron desensitization), 2) increased anandamide via FAAH inhibition, 3) glycine receptor alpha-3 modulation (inflammatory pain suppression), 4) inhibition of pro-inflammatory cytokine release (TNF-alpha, IL-1beta, IL-6).

### Clinical Evidence

Argueta et al. (Journal of Cannabis Research, 2020) reviewed 25 RCTs showing cannabinoids (including CBD-dominant preparations) demonstrate moderate analgesic effects for neuropathic and chronic pain. Best results were seen in neuropathic pain and MS-related spasticity.

Nabiximols (Sativex) — a 1:1 CBD:THC combination — is approved in 25 countries for MS spasticity. CBD monotherapy shows more modest but statistically significant results in fibromyalgia and arthritis.

CBD for Anxiety

### Molecular Mechanisms

CBD anxiolytic effects work through: 1) serotonin 5-HT1A receptor agonism (similar to buspirone), 2) GABAergic neurotransmission modulation, 3) reduced amygdala activity (fear center), 4) hippocampal neurogenesis via increased BDNF.

### Key Studies

Bergamaschi et al. (Neuropsychopharmacology, 2011): single CBD 600 mg dose significantly reduced anxiety, cognitive impairment, and discomfort during public speaking in patients with social phobia. Effect comparable to benzodiazepines but without sedation.

Zuardi et al. (Journal of Psychopharmacology, 2017): CBD 300 mg reduced anxiety in a simulated public speaking test in healthy volunteers. Notably, 150 mg and 600 mg were less effective — a typical inverted U-shaped dose-response curve.

Shannon et al. (The Permanente Journal, 2019): CBD 25-75 mg/day for 3 months reduced anxiety in 79.2% and improved sleep in 66.7% of patients. Anxiety scores remained improved throughout the observation period.

CBD for Neuroinflammation

Neuroinflammation — chronic activation of microglia and astrocytes — is recognized as a key mechanism in neurodegenerative diseases (Alzheimer's, Parkinson's), depression, and chronic pain.

CBD modulates neuroinflammation through: inhibiting microglial activation (M1 to M2 phenotype switching), reducing pro-inflammatory cytokine production, activating PPARgamma receptors, and enhancing antioxidant systems (increasing glutathione).

Fernandez-Ruiz et al. (British Journal of Clinical Pharmacology, 2013) review: CBD demonstrates neuroprotective potential in models of Alzheimer's, Parkinson's, multiple sclerosis, ALS, and Huntington's disease.

Practical Guide

### Forms and Bioavailability

• Sublingual (oil under tongue): bioavailability 13-19%. Onset: 15-30 minutes. Recommended form. - Oral (capsules, gummies): bioavailability 6-13% (first-pass liver metabolism). Onset: 30-90 minutes. - Inhaled (vape): bioavailability 31-56%. Onset: 1-3 minutes. Not recommended due to lung risks. - Topical (creams, balms): local action only, does not enter systemic circulation.

### Dosing

Principle: "start low, go slow" - Starting dose: 10-15 mg/day - Titration: increase by 5 mg every 3-5 days - Standard anxiety dose: 25-50 mg/day - Standard chronic pain dose: 50-150 mg/day - High doses (epilepsy, supervised): 200-600 mg/day

### Choosing Quality CBD

1. Full-spectrum vs Broad-spectrum vs Isolate: Full-spectrum contains all cannabinoids (including trace THC <0.3%), providing the "entourage effect." Broad-spectrum is THC-free. Isolate is pure CBD. 2. CO2 extraction: supercritical CO2 extraction is the gold standard for purity. 3. Certificate of Analysis (COA): from independent lab. Check: CBD content, THC (<0.3%), heavy metals, pesticides, mycotoxins. 4. Source: hemp grown in the EU or USA with GMP certification.

Drug Interactions

CBD inhibits cytochrome P450 enzymes (CYP3A4, CYP2C19), slowing the metabolism of several medications: - Anticoagulants (warfarin) — increased INR - Benzodiazepines (diazepam, midazolam) — enhanced sedation - Anticonvulsants (clobazam) — elevated N-desmethylclobazam levels - Statins — increased concentration - Immunosuppressants (cyclosporine, tacrolimus) — elevated levels

Legal Status

CBD legal status varies significantly by country. In the EU, CBD products from industrial hemp (<0.3% THC) are legal in most countries. In the USA, federally legal after the Farm Bill (2018). In Thailand, legalized since 2022. Always check local regulations.

Frequently Asked Questions

Does CBD cause intoxication? No. CBD has no psychoactive properties. THC is the psychoactive component. Full-spectrum CBD contains <0.3% THC — insufficient for any psychoactive effect.

Will CBD show on a drug test? Isolate and Broad-spectrum should not. Full-spectrum at high doses could theoretically cause a false positive for THC. For regular testing, Broad-spectrum is recommended.

Is CBD safe long-term? Safety data extends to approximately 2 years. Main side effects: diarrhea, fatigue, appetite changes. At doses >300 mg/day, liver enzyme monitoring is advised.

What dose should I start with for anxiety? 10-15 mg sublingually in the evening. Increase by 5 mg every 3-5 days to 25-50 mg/day. Effect typically appears within 1-2 weeks.

*This article is for educational purposes only. CBD may interact with medications. Consult your physician before starting supplementation.*

🌀

Hepatotoxicity: Monitoring Protocol and Threshold Values

The hepatic safety signal for CBD is concrete, dose-dependent, and underappreciated in over-the-counter use. In the Epidiolex pivotal trials for Dravet and Lennox-Gastaut syndromes, alanine aminotransferase (ALT) elevation above 3× the upper limit of normal (ULN) occurred in approximately 13% of patients on 20 mg/kg/day, versus 1% on placebo PMID: 28538134. The vast majority of elevations occurred within the first 8 weeks of therapy, and most were asymptomatic. Concurrent valproate or clobazam significantly amplified the risk.

A 2019 mechanistic study in healthy volunteers (Watkins et al.) reported that CBD 1500 mg/day for 3.5 weeks produced ALT >3× ULN in 5 of 16 subjects, with one case exceeding 10× ULN. This established that CBD-induced hepatocellular injury is not confined to pediatric epilepsy populations or polypharmacy contexts; it is a direct, dose-related phenomenon.

Clinical monitoring protocol (adapted from Epidiolex prescribing information and applicable to any CBD regimen above 300 mg/day):

• Baseline panel before initiation: ALT, AST, total bilirubin, alkaline phosphatase. - Repeat at week 4, week 8, and week 12 of therapy. - After dose escalation: repeat within 4 weeks of the new dose. - After 3 stable months: every 6 months while on therapy.

Reference ranges and action thresholds:

• ALT 19-25 U/L (female) and 29-33 U/L (male) — upper limits recommended by AASLD; classical lab cutoffs of 40-55 U/L underestimate injury. - ALT 3-5× ULN with symptoms (nausea, right upper quadrant pain, fatigue, jaundice) — discontinue CBD and refer. - ALT >5× ULN without symptoms — reduce dose by 50% and recheck in 1 week. - ALT >3× ULN with bilirubin >2× ULN — Hy's law criterion; discontinue immediately, hepatology consultation.

For doses below 100 mg/day in adults without concurrent hepatotoxic agents, the risk appears clinically negligible based on the Shannon cohort and FDA post-marketing surveillance. Patients on statins, methotrexate, isoniazid, valproate, or amiodarone, and patients with pre-existing NAFLD (ALT >30 U/L or steatosis on imaging), should not exceed 50 mg/day without baseline monitoring. Alcohol use above 14 g/day during CBD therapy compounds risk and should be quantified at intake.

🌀

Pediatric Epilepsy Dosing: The Epidiolex Protocol

The article references Epidiolex as the regulatory legitimization of CBD but does not specify the dosing on which that approval was based. The dosing protocol matters because it defines the only context in which CBD has been studied at high doses with hepatic monitoring and standardized outcomes.

Approved indications include Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients aged 1 year and older. The titration schedule from the FDA label and pivotal trials PMID: 28538134, PMID: 28349316:

• Starting dose: 2.5 mg/kg twice daily (5 mg/kg/day total), administered orally. - After 1 week: increase to 5 mg/kg twice daily (10 mg/kg/day) — this is the recommended maintenance dose. - For inadequate response: titrate weekly in 2.5 mg/kg twice-daily increments up to a maximum of 10 mg/kg twice daily (20 mg/kg/day).

Pharmacokinetic considerations:

• Administer with food. A high-fat meal increases Cmax approximately 5-fold and AUC 4-fold versus fasting state. Consistent fed-state dosing reduces seizure breakthrough. - Steady state is reached in 2-4 days. - The active metabolite 7-OH-CBD contributes meaningfully to antiseizure activity.

Efficacy benchmarks from the GWPCARE trials:

• Dravet syndrome: 43% reduction in convulsive seizure frequency on 20 mg/kg/day versus 27% on placebo over 14 weeks [PMID: 28538134](https://pubmed.ncbi.nlm.nih.gov/28538134/). - Lennox-Gastaut syndrome: 44% reduction in drop seizures on 20 mg/kg/day versus 22% on placebo [PMID: 30157131](https://pubmed.ncbi.nlm.nih.gov/30157131/). - Tuberous sclerosis complex: 48.6% reduction on 25 mg/kg/day versus 26.5% on placebo.

The clobazam interaction is the dominant practical issue. CBD inhibits CYP2C19, raising the active metabolite N-desmethylclobazam by 3- to 5-fold. Approximately half of the apparent antiseizure benefit in early trials was attributable to this interaction. When CBD is added to clobazam, the clobazam dose typically requires a 25-50% reduction to manage sedation. This protocol is not extrapolable to over-the-counter CBD oil; Epidiolex is a pharmaceutical-grade isolate with validated content and is not interchangeable with consumer products.

🌀

Contraindications and Special Populations

The article omits a structured contraindications section. Three populations warrant explicit caution.

Pregnancy. The FDA has not approved CBD in pregnancy, and the data are insufficient to establish safety. Animal studies of high-dose CBD in pregnant rats and rabbits demonstrated reduced fetal body weight, embryo-fetal mortality, and male reproductive organ developmental effects at exposures comparable to the human therapeutic range PMID: 30227498. THC, present at <0.3% in full-spectrum products, crosses the placenta and is associated with reduced birth weight and neurodevelopmental effects. Recommendation: avoid all CBD products throughout pregnancy and during attempts to conceive.

Lactation. CBD distributes into breast milk based on its lipophilicity (log P approximately 6.3) and has been detected in milk samples from cannabis users for up to 6 days after last use. The infant's hepatic CYP system is immature, prolonging exposure. The American Academy of Pediatrics recommends against cannabinoid use during breastfeeding.

Hepatic impairment. Per the Epidiolex label, no dose adjustment is needed for mild impairment (Child-Pugh A). Moderate impairment (Child-Pugh B) requires reducing the starting and maintenance dose to 50% of standard; severe impairment (Child-Pugh C) requires a starting dose at 25% of standard with slower titration. Patients with cirrhosis, decompensated NAFLD, or active hepatitis should not initiate CBD without hepatology input.

Other relative contraindications:

• Concurrent warfarin without INR monitoring (CBD raises INR through CYP2C9 inhibition). - Solid organ transplant on tacrolimus or cyclosporine (CBD raises trough levels and may precipitate nephrotoxicity). - Active or recent (<30 days) substance use disorder involving sedatives. - Severe bradycardia or sinus node dysfunction (CBD is bradycardic at high doses). - Children under 1 year and patients with unexplained transaminitis at baseline.

🌀

CBD, Blood Pressure, and Metabolic Effects

The endocannabinoid system intersects directly with cardiometabolic regulation, making this clinically relevant to endocrinology readers. CB1 receptor activity in adipose tissue and the liver promotes lipogenesis and insulin resistance; rimonabant, a CB1 inverse agonist, produced weight loss and improved glycemic parameters before being withdrawn for psychiatric adverse effects. CBD's effects are distinct and more favorable.

Blood pressure. Jadoon et al. (2017) conducted a randomized crossover trial in 9 healthy men: a single oral dose of CBD 600 mg reduced resting systolic blood pressure by approximately 6 mmHg and blunted the pressor response to mental stress and cold pressor testing. A 2020 follow-up using 7 days of CBD 600 mg/day reported sustained reductions in mean arterial pressure of 5 mmHg, with concurrent reductions in arterial stiffness measured by pulse wave velocity. These findings are preliminary, with small samples and male-only cohorts, but the signal is consistent with vasodilation mediated by 5-HT1A agonism and endothelial anandamide elevation.

Glycemic and lipid parameters. A small randomized trial in non-insulin-treated type 2 diabetes patients (Jadoon et al., 2016) tested CBD 100 mg twice daily for 13 weeks. CBD did not significantly change HbA1c or fasting glucose, but lowered resistin and increased glucose-dependent insulinotropic peptide versus placebo. The clinical significance remains unclear, and CBD should not be positioned as a glycemic agent.

Practical considerations:

• Patients on antihypertensives may require dose review after 4 weeks of CBD initiation, particularly those on combination therapy including alpha-blockers or vasodilators. - Orthostatic blood pressure should be checked at week 2 and week 4 in patients over 65 years. - CBD has no established role in weight management; cited claims of CBD-driven fat loss are not supported by controlled human data.

🌀

CBD and Sleep Architecture

The Shannon cohort reported sleep improvement in 66.7% of patients, but the article does not describe the underlying mechanism or distinguish anxiolytic effects from primary sleep effects. This distinction matters because CBD's effect on sleep is heterogeneous and dose-dependent.

Mechanistically, CBD modulates sleep through three pathways: serotonergic 5-HT1A activation reducing sleep latency; adenosine reuptake inhibition increasing sleep pressure; and reduction of cortisol-mediated arousal at doses above 300 mg.

Polysomnographic data. Linares et al. (2018) reported that CBD 300 mg did not significantly alter sleep architecture (REM, slow-wave sleep, sleep efficiency) in healthy volunteers, suggesting absence of the REM suppression seen with most hypnotics. A 2023 randomized trial in chronic insomnia (Saleska et al.) using CBD 15 mg combined with CBN 15 mg for 28 nights reported a 36% reduction in nighttime awakenings versus 12% on placebo, with no morning residual sedation on the Karolinska Sleepiness Scale.

Practical dosing for insomnia:

• Sleep-onset insomnia: 15-25 mg sublingually 30-45 minutes before bed. - Sleep-maintenance insomnia: 25-50 mg sublingually 30-45 minutes before bed, optionally combined with a non-prescription melatonin 0.3-1 mg. - Avoid doses above 75 mg for sleep indication; higher doses may paradoxically increase wakefulness due to inverted U-shaped dose response. - Duration: reassess at 4 weeks; if no benefit, discontinue rather than escalate.

Sleep effects should be distinguished from chronic anxiety effects, which require steady-state dosing across the day. For isolated insomnia without daytime anxiety, evening-only dosing is sufficient and minimizes total exposure.